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Cellular senescence is a state of the permanent cell cycle arrest caused by different stresses or 
cell to cell fusion. Senescent cells, unlike naturally aged cells, exhibit a specific phenotype, 
referred to as senescence associated phenotype (SASP). It is characterized by the production 
of biologically active substances such as interleukins, chemoattractants or proteases that affect 
their surroundings. Long-term survival of these cells in the body is the cause of age-related 
diseases. Under normal circumstances, number of senescent cells is maintained in the body by 
the immune system. However, the age-related abrogation of immune system function per se 
(immunosenescence) contributes  to accumulation of senescent cells in tissues and ageing of 
organism. This work describes origin, positive and negative effects of cell senescence, 
elimination of senescent cells by the immune system and current state of development of new 
substances causing specific lysis (killing) of senescent cells (senolytics). 
Key words: senescent cells, senescence-associated secretory phenotype, DNA damage 
response, physiology and pathophysiology, age-related diseases, apoptosis, senolytics 
 
Abstrakt 
Bunečná senescencia je stav permanentného zastavenia bunečného cyklu zapríčineného rôznym 
stresom či bunečnou fúziou. Takéto bunky na rozdiel od prirodzene starých buniek vykazujú odlišný 
fenotyp označovaný ako fenotyp súvisiaci so senescenciou (SASP). Ten je charakteristický 
produkciou biologicky aktívnych látok, ako sú napríklad interleukíny, chemoatraktanty či proteázy, 
ktoré ovplyvňujú svoje okolie. Dlhotrvajúce prežívanie týchto buniek v organizme je príčinou chorôb 
súvisiacich s vekom. Za normálnych okolností je ich množstvo v tele udržiavané imunitným 
systémom, ktorý však stráca svoju funkciu. To je pravdepodobne príčinou ich hromadenia a 
negatívnych následkov na starnúcom organizme. Táto práca popisuje vznik, pozitívne a negatívne 
účinky senescencie, ich elimináciu imunitným systémom a látkami spôsobujúcimi ich lýzu 
(senolytika). 
Kľúčové slová: senescentné bunky, fenotyp súvisiaci so senescenciou, odpoveď DNA poškodenia, 
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1 Introduction  
 
 Ageing is the risk factor for chronic diseases, because senescent cells can accumulate with age 
and have negative effect on microenvironment, what is promote by their phenotype. These cells are 
most often arrested between G1-S phases of the cell cycle (Gire and Dulić, 2015). The cell cycle arrest 
is induced by the control mechanisms, which ensure the correct course of the cell cycle without 
disrupting gene integrity. DNA instability or damage can be induced by various means, such as 
ionizing radiation, depletion of the replication potential, drugs, toxins or increased expression of 
oncogenes. These stressors induce DNA damage response, whose permanent presence induce cellular 
senescence. Cellular senescence can also be induced by cytokines or cell fusion that plays a role in 
fetal development (Gioscia-Ryan et al., 2013). 
 Short-time presence of the senescent cells in an organism have positive effect on regeneration, 
wound healing and embryogenesis. However, long-time presence of senescent cells has detrimental 
impact on tissue microenvironment which is associated with age-related diseases such as, for example, 
atherosclerosis, osteoporosis or cancer. In the development of the chronic presence of senescent cells 
is also implicated immune system, which loses function in their clearance (Burton and Krizhanovsky 
2014). 
 The healthspan and reduction of development chronic diseases can be enhanced by selectively 
killing of the senescent cells. The change in metabolism, cell surface and anti-apoptotic signalizing are 
targets for senolytics. The main purpose of this work is to provide current state of strategies directed to 












2 Cellular senescence  
 
 Cellular senescence was first described by L. Hayflick in 1961 as a state when cells 
(embryonal fibroblasts) cannot divide anymore after about 50 population doublings (Hayflick, 
Moorhead, 1961). This loss of proliferation potential (Sherwood et al., 1988) is due to inhibition of 
cyclin-dependent kinases (Cdks) by elevated levels of protein inhibitors of the Cdks (Cdki). The 
expression or stabilization Cdki can be activated by multiple mechanisms including DNA damage, 
oxidative stress (Passos, Saretzki and Von Zglinicki, 2007; Salama et al., 2014), cytokines (Scandura 
et al., 2004), or bacterial toxins (Blazkova et al., 2010). Trigger of oxidative stress are reactive oxygen 
species (ROS) that accumulate as a result of either impaired mitochondria, increased NADPH oxidase 
activity (Lener et al., 2009) or xanthine oxidase activity (Kuppusamy and Zweier, 1989).   
 Cdki comprise two families, INK4 (p16INK4a, p15INK4b, p18INK4c, p19INK4d) and Cip/Kip 
(p21waf1/cip1, p27Kip1, p57Kip2). The INK4 proteins inhibit the activity of the CDK4 in G1 phase of the 
cell cycle. The second family of Cdki decrease the activity of complex Cdks with A, D or E cyclins. 
However, p21waf1/cip1 (p21) and p27Kip1  (p27) proteins stabilize the complex cyclin D-Cdk in G1 phase 
of the cell cycle (Sherr and Roberts. 1999). The p21 can be induced by the action of transcription 
factor p53, a tumour suppressor gene that is mostly stabilized in response to DNA damage (Chang et 
al., 2007; Brown et al., 2014). Cyclin D-Cdk4 complex phosphorylates inhibitor of the E2F 
transcription factors, retinoblastoma protein (pRB). This allows the transcription of cyclins E and A, 
and a transition to the S phase of the cell cycle (Sherr and Roberts, 1999). One of the downstream 
targets of E2F is protein p14ARF, which stabilizes pRB by the inhibition of its ubiquitin E3 ligase 
MDM2, and also the non-phosphorylated pRB allows to inhibit the cell cycle via the p53-p21 pathway 
(see Figure 1) (Chang et al. 2007). 
 Stopping the cell cycle in G1 phase is more frequent than in the G2 phase, because G1 
checkpoint appear to be more efficient (Gire and Dulic, 2015). Furthermore, skipping cytokinesis in 
mitosis, as is frequently observed during development of cell senescence, results in formation of 













Figure 1: Senescence response: triggers, pathways, features and markers. (Based on the diagram from 
Natalia Loaiza, Marco Demaria, 2016). 
 
 The characteristic feature of senescent cells is an increase of cell volume, elevated levels of 
proteins p16, p53, p21, elevated activity of senescence-associated β-galactosidase (SA-β-gal) and 
accumulation of lipofuscin (Kirkland et al., 2017). However, the p21 level decreases over a longer 
duration of senescence (Stein et al., 1999). Senescent cells have enlarged cell volume with an 
increased number of actin filaments (Kassem et al., 1997). The cause of cell growth and accumulation 
of proteins is deregulated mTOR activity, which promotes protein translation and facilitates 
interleukin 6 (IL-6) and interleukin 8 (IL-8) synthesis (Narita et al., 2012). Protein accumulation is 
also caused by decreased glycogen synthase 3 (GSK3) activity (Kim et al., 2010). 
 Genes responsible for proliferation are silenced by heterochromatinization forming 
senescence-associated heterochromatin foci (SAHF), but this is not typical for all senescent cell types 
as it is dependent on the type of senescence induction. For example, in keratinocytes, human dermal 
(BJ) and mouse embryonic fibroblasts (MEFs), the presence of SAHF was not found. p16 is likely to 
play a role in the formation of SAHF which together with hypophosphorylated pRB protects cells 
against possible malignant transformations (Kosar et al., 2011).  
 Senescent cells produce cytokines, chemokines, pro-thrombotic factors, extracellular proteases 
and other biologically active factors (Lasry and Ben-Neriah, 2015). This production of bioactive 
compounds is referred as senescence-associated secretory phenotype (SASP) and the quality and 
quantity of SASP depend on the type of senescent cells (Coppé, Desprez and Krtolica, 2014).  
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 The expression of the SASP gene loci is enabled by high mobility group box 2 (HMGB2), 
which protects them from heterochromatinization (Aird et al., 2016). The major products are IL-6 and 
IL-8, which are activated by transcription factors NF-κB (nuclear factor-kappa B) and C/EBPβ 
(CCAAT/enhancer binding protein beta) (Guerrero and Gil, 2016). The upstream signal for their 
production are interleukin 1α (IL-1α) signalizing (Orjalo et al., 2009) and p38 mitogen-activated 
protein kinase (p38MAPK) pathways triggered by DNA damage response (DDR) cascade (Bredeson 
































3 Mechanisms of cellular senescence 
 
 In general, the cell cycle arrest can be caused by various stress factors that interfere with 
cellular integrity during cell cycle progression. Exhaustion of replication potential, attrition of 
telomeres together with their irreparable damage and so-called end-replication problem (Olovnikov, 
1973) are thought as causes of replicative senescence. Note that epithelial and endothelial cell 
senescence have different mechanisms and characteristics compared to replicative senescence of 
fibroblasts. Two senescent states are described for epithelial cells, the first one in keratinocytes and 
mammary epithelial cells is DDR-independent, unlike senescence of fibroblasts. The second is caused 
DDR pathway or p16/Rb pathway (Brenner et al,, 1998; Nassour et al., 2016; Abbadie et al., 2017a). 
 Besides replicative senescence, other types of senescence caused by various stress stimuli 
were described. These types of senescence are referred to as Stress-Induced Premature Senescence 
(SIPS) and can be further divided according to type of stimulus as oncogene-induced senescence (OIS) 
induced by hyperactivation of oncogenes (Serrano et al., 1997), drug-induced senescence induced by 
various chemicals including chemotherapeutics (Petrova et al., 2016), bacterial toxin-induced 
senescence  induced by some bacterial toxins with genotoxic activity (Hassane et al., 2003), cytokine-
induced senescence triggered by autocrine or paracrine action of some cytokines (Frippiat et al., 
2001). 
 
3.1 Replicative senescence 
3.1.1 Replicative senescence of fibroblast 
 As mentioned above, in the Hayflick production of fibroblasts in vitro, the cells had a limited 
number of divisions. This number of doublings depends on cell culture conditions. Experiments with 
mouse embryonic fibroblasts (MEF) grown in high or low oxygen concentration, or whose antioxidant 
status has been modified, have shown that hyperoxia caused shortened cell culture lifespan in cell 
populations grown in 20% oxygen whereas cell cycle arrest was not observed in cultures grown at 3% 
oxygen. Addition of hydrocortisone and α-tocopherol or bovine serum albumin into growth medium 
increased population doubling (Lu and Finkel, 2008).  
 Human telomeres are composed of DNA repetitive sequences 5´-TTAGGG-3´ with a single-
stranded 3´ extension strand. This overhang creates the t-loop and d-loop structures that close the 
telomere end (Boeck and Forsyth, 2010). Telomeric repeat-binding factors TRF1 and TRF2F are 
important for formation of t- and d-loops, which protect double-strands DNA (dsDNA) segments of 
the telomeres (Martínez and Blasco, 2015). They are a part of multiple telomere-specific binding 
proteins, which make up the structure called "shelterin"  (Boeck and Forsyth, 2010) (see Figure 2). 
These proteins inhibit the activity of checkpoint kinases ATM (ataxia telangiectasia mutated), ATR 
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(ataxia telangiectasia and Rad3 related) in DDR  involved in DNA repair (Karlseder et al., 2004). This 
pathways are activated by shortened and/or deprotected telomeres, DNA double-strand breaks (DSBs), 





















Figure 2: Telomere structure and shelterin (based on the diagram from Martínez, Paula Blasco, Maria 
A., 2015). 
 
During cellular lifespan the telomeres can be damaged, the telomeric damage can be repaired by 
telomerase activity in proliferating and tumour cells (Harley et al., 1990; Olovnikov, 1973). The 
enzymatic activity of human telomerase reverse transcriptase (hTERT) prolongs the 3´ends of 
telomeres, and these allow the DNA polymerase to elongate the second strand DNA of the 
chromosome terminals (Wu et al. 2006). It is thought that too short or uncapped and unrepaired 
telomeres can result in cellular senescence (Blackburn, 2001; Herbig et al., 2004) (see Figure 3.).  
 Damage in telomeric repeats may be caused with elevated levels of reactive oxygen species 
(ROS) because guanine is prone to oxidation (Oikawa et al., 2001). Consequently, the single-strand 
DNA break (SSB) or DSBs arising in consequence of DNA repair of oxidative DNA damage can 
trigger the DDR. In addition, ROS decline the activity of telomerase and this can lead again to cell 
cycle arrest (Passos et al., 2007). Mechanistically, high intracellular levels of ROS induced by the 
RAS–RAF–MEK–ERK cascade activate the p38MAPK, which leads to increased transcriptional 




Figure 3: Mechanism of replicative senescence (adopted from Deng et al., 2008).  
 
3.1.2 Replicative senescence of epithelial and endothelial cells 
 Endothelial cells are the specialized cells that line the vascular lumen in a single layer. 
Senescence in endothelial cells is manifested by elevated SA-β-gal activity and p53/p21 pathway. In 
the vein smooth muscle cells (VSMC) is senescence associated with reduced TRF2 expresion and its 
loss in telomere, what is caused DDR (Bennett et al., 2015). The main feature of cells that, after the 
shape change described as VSMC-like, endothelial-like, foamy macrophage-like, is the increase of the 
expression of p16. Early foam macrophage cells produce chemoatractants for leucocytes and 
monocytes, which together with them support development of atherogenic plaques (Childs et al., 
2016)These senescent cells also degrade elastic fibers and plaque calcification leads to atherosclerosis. 
The removal of the foam macrophage-like cells results in the suppression of atherogenic plaque 
formation (Min et al., 2007; Childs et al., 2016).  
 In epithelial cells, such as keratinocytes and mammary epithelial cells, senescence is telomere 
and DDR-independent. Activation of senescence by the p16 pathway was also detected in other cells 
with or without the presence of telomere damage, which differs from senescence in fibroblasts. In the 
cell cycle arrest of fibroblast are present both pathways, p53/p21 and p16/RB, but in the epithelial 
cells only p16/RB (Abbadie et al., 2017). The p16 protein is induced by p38MAPK activity, which is 
activated in the presence of DNA damage, oxidative stress and other stress conditions. The senescence 
in epithelial cells is primarily caused by SSB and p16/p38MAPK pathway (Abbadie et al., 2017b). 
 Epithelial senescent cells have a distinct SASP. In keratinocytes and epithelial colon cells was 
detectable maspin, which has tumour-suppressor and anti-angiogenic effects. It was not detected in the 
senescent fibroblasts, nevertheless maspin affects their proliferation. With increasing age the level of 
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the maspin is increased and plays role as an antagonistic factor for malignant fibroblast 
transformation. With increasing age the level of the maspin increased (Nickoloff et al., 2004). 
 
3.2 Premature types of cellular senescence 
3.2.1 Oncogene-induced senescence 
 Oncogenes are mutant versions of normal genes that have the potential to transform cells in 
conjunction with additional mutations. Normal cells respond to many oncogenes by undergoing 
senescence. This phenomenon was first observed when an oncogenic form of RAS, a cytoplasmic 
transducer of mitogenic signals, was expressed in normal human fibroblasts (Collado, Blasco and 
Serrano, 2007), which was later shown to be telomere-independent type of senescence triggered by 
onco-proteins (We et al., 1999).                                            
 Cell cycle arrest occurs after the deregulation of oncogenes, which is mainly accompanied by 
persistent DDR signalling in response to DSBs or unprotected telomeres. These damages on DNA can 
be immunofluorescent detected for the phosphorylated histone H2A.X (γH2AX) and the adapter 
protein tumour suppressor p53-binding protein 1 (53BP1). It is referred to as DNA damage foci or 
DNA segments with chromatin alterations reinforcing senescence (DNA-SCARS) and marker of the 
senescence (Rodier et al., 2011).  
 The effect depends on the type of the oncogene and on the cellular context. For example, 
activated oncogene Ras increases p53 and ARF, which have preventive effects on the oncogene-
induced transformation (Serrano et al., 1997). Senescence-associated heterochromatin foci caused by 
Ras, suppress the expression of the E2F-induced genes (Narita et al., 2003).  
 A general feature of oncogene-induced senescence is the derepression of the CDKN2A locus 
(Kim and Sharpless, 2006). In addition, this type of senescence may also induce robust DDR owing to 
the DNA damage that is caused by aberrant DNA replication (Bartkova et al., 2006) and/or ROS. The 
relative importance of these mechanisms (p16, ARF or DDR-induced p53) varies across cell types 
(Alimonti et al., 2010). 
 
3.2.2 Drug-induced senescence 
 Premature senescence can be induced in normal and cancerous cells by various chemicals 
depending on their dosage and mechanism of action. Drugs that interact directly with DNA or affect 
chromatin remodelling often cause SIPS. For example, trichostatin A, which inhibits histone 
deacetylases and triggers the p53 protein pathway can induce SIPS (Rebbaa et al., 2006). 
Topoisomerase inhibitors such as doxorubicin, camptothecin, amsacrine, and etoposide also trigger 
p53/p21 pathway by induction of DSBs (Rebbaa et al., 2006; Sabisz and Skladanowski, 2014).  
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 Cell cycle arrest can be also caused by DNA G-quadruplex stabilizers that inhibit, for instance, 
telomerase activity, leading to an accelerated onset of senescence (Huang et al., 2008). Another way 
how to reduce the number of cell divisions and stop the cell cycle is to use inhibitors that interfere 
with nucleotide metabolism or forming mutations of nitrogen bases. An example is cyclopentenyl 
cytidine, which acts as a noncompetitive CTP synthase inhibitor in the form of triphosphate. This 
leads to increase of level p53 protein and overexpression of p53 target genes (Huang et al., 2011). 
 
3.2.3 Bacterial toxin-induced senescence 
 Another pathophysiological stimulus that induces premature senescence are several cytolethal 
distending toxins (CDTs) produced by facultative pathogenic strains of G- bacteria such as 
Escherichia coli, Campylobacter jejuni, Helicobacter hepaticus, Shigella dysenteriae and 
Actinobacillus actinomycetemcomitans have been described and shown to have genotoxic effects on 
cells in vitro (Blazkova et al., 2010). Mammalian cells exposed to these bacterial proteins undergo cell 
type-dependent cell cycle arrest or apoptosis. This characteristic phenotype included persistently 
activated DNA damage signalling (detected as 53BP1/γH2AX foci), enhanced SA-β-gal activity, 
expansion of promyelocytic leukaemia nuclear compartment, expression of several cytokines 
(especially interleukins IL-6, IL-8 and IL-24) and activation of the two major tumour suppressor 
pathways – the p16/RB and p53/p21 cascades, overall features shared by cells undergoing replicative 
or premature cellular senescence (Duane C Hassane, Lee and Pickett, 2003). 
 
3.2.4 Cytokine-induced senescence 
 Cytokines are small signalling proteins that are involved in autocrine, paracrine and endocrine 
signalling as immunomodulating agents through membrane bound receptors. Senescence-inducing 
effect of cytokines on mouse cancer cells was described for cytokines, such as the T helper-1 (TH1)-
cytokines interferon-γ (IFN-γ) and tumour necrosis factor alpha (TNF-) (Braumüller et al., 2013) or 
transforming growth factor-ß (TGF-ß) (Untergasser et al., 2003).  
 Cytokines from the TGF-β family increase ROS in the cell by induction the expression 
NADPH oxidase Nox4 (Burdak et al. 2008). TGF-β induces the cell cycle arrest in cancer cells also by 
direct induction of cdki p21 and p15 (Senturk et al., 2010).   
          For the pro-inflammatory TH1 cytokines, the senescence signalling pathways in mouse beta cells 
have been partially deciphered: permanent growth arrest needs the simultaneous activation of TNF 





4 Physiological roles of cell senescence 
 
 Recent evidence has pointed to beneficial effects of cellular senescence beyond tumour 
suppression, for instance in directing wound repair and in embryogenesis. To achieve this, senescent 
cells arrest their own proliferation, recruit phagocytic immune cells and promote tissue renewal. In 
these contexts, senescence serves a tissue remodelling role and the senescent cells have a relatively 
short half-life, presumably because they are efficiently cleared by immune cells (Storer et al., 2013). 
4.1 Organism development 
 
 Developmental senescence is a physiologically programmed senescence pathway that has 
recently been described to actively contribute to embryonic patterning. This process is also 
accompanied by the SASP that attracts macrophages which in turn seem to be necessary to remove 
senescent cells in a coordinate manner in order to foster the physical development of the embryo 
(Gioscia-Ryan et al., 2013). In embryo, the occurrence of senescence was substantiated by SA-ß-gal 
staining as well as absence of proliferation detected as negative Ki67 staining and 5-bromo-2´-
deoxyuridine (BrdU) incorporation, increased heterochromatin markers such as histone 3 lysine 9 
trimethylation (H3K9me3) and heterochromatin protein 1 homologue-γ (HP1γ), and increased 
expression of cell cycle inhibitors (p15, p21 and p27) (Storer et al., 2013).  
 DNA damage markers were absent in the structures undergoing developmental senescence. 
Altogether, cellular senescence seems to be common throughout the developing embryo, but it has 
distinctive features compared to damage-induced senescence. 
4.2 Megakaryocytes and placental syncytiotrophoblasts 
 
 Apart from embryonic development, senescence also occurs in a physiologically programmed 
manner in adult organisms. In particular, normal megakaryocytes (Besancenot et al., 2010) and 
placental syncytiotrophoblasts (Chuprin et al., 2013) undergo senescence as part of their natural 
maturation programmes. In case of mouse and human megakaryocytes, senescence is characterized by 
SA-β-gal activity, DDR, induction of p21, proliferative arrest and accumulation of HP1γ. 
Megakaryocyte senescence, similar to developmentally programmed senescence, is dependent on p21 
but is independent of p16, p53 or p27 (Besancenot et al., 2010). The human placenta shows marked 
SA-β-gal activity at the syncytiotrophoblast in association with DNA damage markers, p16, p21 and 





4.3 Wound healing and tissue regeneration 
 
 It has been shown that many factors comprising SASP of senescent cells are important for 
tissue repair: growth factors and proteases that participate in wound healing, attractants for immune 
cells that kill pathogens, and proteins that mobilize stem or progenitor cells. Thus, the SASP may 
serve to communicate cellular damage/dysfunction to the surrounding tissue and stimulate repair, if 
needed. Upon acute liver injury in mice, hepatic stellate cells initially proliferate and secrete 
extracellular matrix (ECM) components, which produce a fibrotic scar. Shortly after the proliferative 
stage, stellate cells in the injured liver undergo senescence (Krizhanovsky et al., 2008). This 
senescence response is accompanied by a decline in ECM production and increased secretion of 
several matrix metalloproteinases (MMPs), which are known to degrade ECM proteins. This finding 
suggested that the senescence response helps to resolve the fibrotic scar. When stellate cells are 
compromised for their ability to undergo senescence, mice developed severe fibrosis after acute liver 
injury.  
 Jun and Lau (2010) demonstrated the role of senescence in limiting fibrosis in skin wound 
healing and showed the pivotal role of CCN1 (CYR61) in converting wound-activated fibroblasts into 
senescent fibroblasts. The extracellular matrix protein CCN1 is crucial for the induction of senescence 
in dermal fibroblasts, the associated expression of pro-inflammatory cytokines and antifibrotic MMPs 
(Jun and Lau, 2010).  
 Another important role is the senescence generated by cell fusion in the formation of 
syncytiotrophoblast. This cell-cell fusion-induced senescence (FIS) is provided by the protein 
ERVWE1 (Chuprin et al., 2013). This syncytium of the placenta likely play the role in resistance to 
apoptosis, which is necessary for development of the embryo. Secreted proteases and cytokines 
maintain feto-placental function. Next positive effects of senescence on tumour suppression have been 











5 Pathophysiology of cell senescence 
 
5.1 Cellular senescence as primary tumorigenesis barrier 
 
 Cell senescence represent intermediate stage between normal proliferating cells and tumour 
cells (Serrano, 2011). Telomere shortening has been shown to be responsible for decreased tumour 
formation in telomerase-deficient mice crossed with p53R172P mutant which is unable to initiate 
apoptotic response (Cosme-Blanco et al., 2007). Using this model authors demonstrated that p53-
mediated cellular senescence in the context of telomere shortening acts as a main mediator of tumour 
suppression in this mouse model. Other authors have shown that oncogene-induced senescence acts as 
a barrier to melanoma development in melanocytic nevi, which is associated with activation of 
oncogenic BRAF protein kinase and independent to telomere shortening (Michaloglou et al., 2005). 
RASV12 knock in mice develop lung adenomas characterized by a low proliferative index which was 
associated with the elevation of SA-β-gal activity and induction of other senescence markers (Collado 
et al., 2005).  
 In a mice model for p53-dependent liver cancer, re-expression of p53 in lymphomas and 
osteosarcomas provokes tumour regression by inducing senescence, in a tissue-dependent manner 
(Ventura et al., 2007). Using p53 restoration model showed that senescent cells activate an 
inflammatory program that leads to a dramatic regression of invasive hepatocarcinomas and their 
clearance by the innate immune system (Xue et al., 2015). 
  Altogether the literature data from in vivo studies increasingly support the concept that cellular 
senescence corresponds to a potent physiological mechanism protecting against oncogenic 
transformation which is consistent with results from in vitro studies.  
 
5.1.1 Escape (bypass) of senescence 
 Various tumour suppressors and oncogenes have been shown to act as control mechanism 
regulating senescence in normal cells thus preventing uncontrolled cell proliferation. Escape from 
senescence (senescence bypass) resulting in cell immortalization, on the other side, appears to be an 
important step in the cancer development. Virtually all human cancers lack functional p53/pRB 
pathways (Sherr and Mccormick, 2002) and often carry mutations in sets of genes, which are known to 
collaborate in vitro in bypassing the senescence response. For example, almost all human pancreatic 
cancers suffer from an activating RAS mutation and a deficiency of the INK4A/ARF locus (Bardeesy 




5.2 Senescence-associated secretory phenotyope  
 
 One of the main features of many senescent cells is production of a specific pro-inflammatory 
secretome referred as SASP (see chapter 2 above) The SASP is primarily a property of cells with 
genomic or epigenomic damage. In contrast, cells with detected  DNA damage, dysfunctional 
telomeres, mitogenic signals, oxidative stress, and other senescence-inducing stimuli develop the 
SASP of varying qualities and robustness (Campisi, 2014).  
 As mentioned above SASP components can include several families of soluble and insoluble 
factors (Coppé, 2014), which can affect surrounding cells by activating various cell-surface receptors 
and corresponding signal transduction pathways that may lead to multiple pathologies, including 
cancer. Whereas some SASP factors are known to fuel the deleterious effects of senescent cells, other 
or even the same factors may have beneficial effects. SASP factors can be divided into the following 
major categories: soluble signalling factors (cytokines, chemokines and growth factors), secreted 
proteases, and secreted insoluble proteins/extracellular matrix components. SASP proteases can have 
three major effects: 1) shedding of membrane-associated proteins, resulting in soluble versions of 
membrane-bound receptors, 2) cleavage/degradation of signalling molecules, and/or 3) degradation or 
processing of the extracellular matrix. These activities provide potent mechanisms by which senescent 
cells can modify the tissue microenvironment. SASP components, most notably TGF-ß, can also 
trigger senescence in neighbouring cells in paracrine manner through mechanism that generates ROS 
and DNA damage (Hubackova et al., 2012; Acosta et al., 2013). 
 
5.2.1 SASP in tumour promotion 
 There is mounting evidence that SASP of senescent cells can drive protumorigenic cell 
proliferation. Fibroblasts from the human prostate gland that undergo senescence in culture have been 
shown to create a local tissue environment that favours prostate epithelial cell hyperproliferation 
(Bavik et al., 2006). Matrix metalloproteinases secreted by senescent fibroblasts, in particular MMP3 
(stromelysin) which also promotes tumour cell invasion, have been shown to be responsible for the 
higher tumorigenicity of breast epithelial cell xenografts in mice (Liu et al., 2007).              
Malignant melanocytes express high levels of CXCR-2 receptor and can be stimulated to grow by 
melanoma growth stimulatory activity/growth regulated protein (MGSA/GRO) and IL-8. The 
senescent microenvironment may therefore stimulate the proliferation of rare premalignant cells in 
nevi, thereby leading to the development of melanoma (Wang et al., 2009; Coppé et al., 2014) 
 Besides promoting cell proliferation an array of SASP factors can stimulate cell motility, i. e. 
cell migration, invasion and metastasis. In breast cancer, high levels of IL-6 and IL-8 secreted by 
senescent fibroblasts are responsible for a transition of epithelial cells into mesenchymal ones which is 
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an important morphological transition enabling epithelial cells to invade and migrate through tissues 
and is critical in the development of metastatic cancer (Coppé et al., 2008; Gioscia-Ryan et al., 2013). 
 Senescent cells that senesce in response to DNA-damaging radiation or chemotherapeutics 
secrete some factors (WNT16B, IL-6, tissue inhibitor of metalloproteinases-1) that can protect 
neighbouring tumour cells from being killed by the same chemotherapeutic agents  (Xue et al., 2007). 
 
5.2.2 SASP in immune system suppression 
 SASP includes proteins that can help senescent cells evade immune recognition and clearance 
(Coppé et al., 2010). For example, high secreted levels of matrix metalloproteinases by senescent cells 
can cleave both the cell surface ligands on natural killer target cells and the cell surface receptors on 
natural killer cells, thereby preventing natural killer cells from targeting and killing senescent cells. 
 On the other side, CD8+ T cells are suppressed by the action of IL-6 on myeloid cells. This 
suppression reduces tumour-suppressive immunity in tumours with chronic presence of senescence 
cells in the vicinity (Ruhland et al., 2016; Wang et al., 2018). 
 Another major immune modulator is the programmed cell death ligand 1 (PDL1), which 
permits cancer cell immune evasion by suppressing apoptosis in regulatory T cells and promoting 
death in effector T cells (He et al., 2015). CD4+ T cells, which are involved in senescent cells 
clearance, express the PDL1 receptor, but it is unknown to what extent this ligand is used by senescent 
cells for immune evasion. 
 
5.2.3 SASP in degenerative diseases 
 Senescent cells have been shown to drive degenerative changes that can disrupt normal tissue 
structures essential for normal tissue function, largely through their secreted proteins (Rodier et al., 
2011). Numerous degenerative diseases have been associated with cellular senescence, including 
atherosclerosis, osteoarthritis, Alzheimer disease, chronic obstructive pulmonary disease and 
idiopathic pulmonary fibrosis (Bhat et al., 2012; Bar-Shai et al., 2014; Childs et al., 2016; Schafer, 
2017).  
 Senescent vascular smooth muscle cells and endothelial cells accumulate at sites of 
atherosclerotic lesions and secrete several pro-atherogenic factors, such as IL-1α, monocyte 
chemotactic protein 1, MMP12 and MMP13. Selective elimination of these cells in a mouse model 




 In a mouse model of traumatic osteoarthritis, a factor made by senescent chondrocytes has 
been shown to inhibit cartilage regeneration. Clearance of senescent cells in this system promoted the 
repair of damaged cartilage, possibly due to reduction of levels of SASP factors MMP13, IL-6 and IL-
1β. Clearance of naturally occurring senescent cells in naturally aged mice also prevented age-related 
osteoarthritis (Jeon et al., 2017).  
 In fat tissue, levels of the SASP factors IL-6 and IL-1ß increase with age, and these are known 
to cause insulin resistance when chronically high (Gao et al., 2014). 
 
5.2.4 SASP in ageing 
 Ageing is the progressive loss of tissue and organ function over time (Flatt, 2012). Senescent 
cells accumulate in aged tissues with high SA-β-gal activity and increased expression of the 
senescence master regulator, p16 (Krishnamurthy et al., 2004). keeping senescent cells with age is 
related to their reduction by removing immune mechanisms that become less effective (Burton and 
Stolzing, 2018).  
 In vitro studies suggest that cell senescence promote deterioration of tissue maintenance 
processes due to the SASP and disrupt reparative stem and progenitor cells from the proliferative pool. 
SASP factors that were described to have in vivo functions in ageing are cytokines IL-6 and TNF-α 
(Starr et al., 2015). Optimal function of stem cells depends on their highly specialized 
microenvironment (O’Connor, 2009) and therefore SASP may deleteriously affect stem cells by 
altering this microenvironment. For example, metalloproteinases which are prominent compounds of 
SASP could destroy the polarized extracellular matrix. The SASP could also affect parenchymal cell 
function and tissue composition without influencing stem cells. Structural changes caused by the 
secretion of matrix metalloproteinases could damage surrounding extracellular matrix, potentially 
leading to effects such as loss of skin or lung elasticity (Liu et al., 2007). The SASP of senescent cells 
can directly affect the endocrine-responsive intracellular signalling cascades through TNFα, IL-1ß 
and/or IL-6, secretion of which cause resistance to IGF1 signalling (O’Connor, 2009).  
 In ageing skin, accumulation of senescent cells has been shown both in the epidermis and the 
dermis (Nassour et al., 2016). The generation of reactive oxygen species and the degradation of the 







6 Removal of senescent cells by immune system 
 
 Induction of cellular senescence commonly coincides with an immunogenic phenotype that 
promotes self-elimination by components of the immune system, thereby facilitating tumour 
suppression and limiting excess fibrosis during wound repair (Sagiv et al., 2016). The mechanism by 
which senescent cells regulate their immune surveillance are not completely understood. 
Proinflammatory secretome of senescent cells attract immune cells of the innate and adaptive immune 
system (Xue et al., 2007; Kang et al., 2011) which kill and remove senescent cells. Among the cells 
that participate in the clearance of senescent cells are natural killer cells, macrophages and T cells 
(Xue et al., 2007; Krizhanovsky et al., 2008). 
 The effect of senescent cell on the organism is regulated by the immune system, which control 
their frequency, but long-lasting presence adversely affects neighbouring cells and tissues. The role of 
the immune system is to prevent the long-term presence of senescent cells in the body that is failing 
together with age and is probably the cause of age-related diseases (Burton et al., 2018). For example, 
the CD4+ T cell, promote the anti-tumour role of immunity by eliminating premalignant senescent 
cells in liver by macrophages or monocytes (Kang et al., 2011). The senescent cells show changes in 
the membrane, such as modified vimentine (Frescas et al., 2017), oxidation-modified phospholipids 
(Ademowo, 2017), modified glycolipids (Itakura et al., 2016), and loss of CD47 phagocytosis 
inhibitory protein (Liu et al., 2017). These changes may have role in removal of senescent cell by the 
macrophages (see Figure 4).  
 Senescent cells or other stressed cells (e.g. tumour, virus-infected cells) have increased 
expression of the NKG2D ligands. NKG2D receptor is on the membrane of the natural killer (NK) 
cells, which recognize MICA and ULBP1-6 ligands. The type of ULBP ligand depend on the cell type 
and cause of cell senescence, but their expression is not based on DDR, unlike MICA. Their 
elimination is promoted by chemoattractants and cytokines, what facilitate faster recognition by the 
NK (Sagiv et al., 2016). 
 Cancer cells can escape programmed immune clearance through a combination of decoy 
receptor presentation, immunomodulatory cytokines and checkpoint ligands. Decoy receptors DCR2 
and DCR3 expressed widely on cancer cells titrate away FAS ligand and TNF-related apoptosis-
inducing ligand that are presented by cytotoxic T cells, thereby blocking apoptosis (Wu et al., 2014). 
Similarly, hepatic senescent cells produced by liver injury as well as senescent cells that result from 
other stimuli have upregulated levels of DCR2 which neutralizes activation by FAS-mediated extrinsic 





Figure 4: Possible mechanisms of senescent cell recognition by macrophages (based on the diagram 


















7 Strategies of pharmacological removal of senescent cells 
 
 The finding that killing senescent cells in vivo increases healthspan in mice and delays 
multiple age-related symptoms and pathology (Baker et al., 2011) has opened the door for the 
development of agents and strategies to specifically target senescent cells for the prevention and 
treatment of age-related diseases. These strategies comprise the selective elimination of senescent cells 
(senolysis), suppressing onset of senescence, immune-mediated clearance of senescent cells and SASP 
neutralization.  
 
7.1 Specific features of senescent phenotype as target of their removal 
 Senescent cells are inherently diverse in various aspects: senescent cells of different origins 
secrete different SASP factors (Coppé et al., 2008), drive disease pathogenesis through varying 
mechanisms and can be triggered to enter apoptosis through distinct senolytic mechanisms 
(Sturmlechner et al., 2017). Some features of all senescent cells can potentially be exploited for 
senotherapy, e.g. the proliferation cessation (growth arrest) which is essentially irreversible, resistance 
to cell death signals (apoptosis resistance), widespread changes in gene expression and pro-
inflammatory secretion profile.  
 
7.1.1 Resistance to apoptosis 
 One of the most prominent features of senescent cells, at least in cell culture, is that they show 
alterations in apoptotic signalling which causes their relative resistance to programmed cell death 
(Burton et al.,2015). Unlike normal cells, senescent cells are protected from both intrinsic and 
extrinsic pro-apoptotic signals that allow them to persist and promote diverse biological processes 
under stress conditions (Sagiv et al., 2013). Targeting these apoptotic pathways preferentially in 
senescent cells can result in selective death of these cells and preventing them from exerting their 
detrimental effects (Ovadya et al., 2018).  
 One key determinant of the senescent versus apoptotic cell fate choice is signalling through 
the p53 stress response pathway. Recent studies highlight the p53/p21 axis as a promising target for 
development of novel senolytics (Baar et al., 2017; Yosef et al., 2017). Interfering in direct interaction 
of p53 with the transcription factor FOXO4 leads to the release of p53 from the nucleus and induction 
of cell-intrinsic apoptosis. Administration of a modified FOXO4/ p53-interfering peptide was able to 
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neutralize murine liver chemotoxicity of doxorubicin treatment and restore fitness, hair density, and 
renal function in progeroid and naturally aged mice (Baar et al., 2017).  
 p21 itself can block apoptosis and apoptotic cells actively silence p21 expression via p53-
dependent DNA (cytosine-5)-methyltransferase 3A (DNMT3A) activity (Zhang et al., 2011). In mice, 
p21 knockout leads to a reduction of senescent cells in fibrotic livers and alleviates liver fibrosis 
(Yosef et al., 2017). Therefore, the development of drugs that can induce apoptosis in senescent cells 
by inhibition of p53 or p21 is a promising strategy to target senescent cells. For example quercetin 
(Zhu et al., 2015) and agmatine (Song et al., 2016).  
 Senescent cells are characterized by a state of permanent growth arrest and their prolonged 
survival. Several of the senescent cells pro-survival pathways that have been identified can be utilized 
for directed elimination of senescent cells. Currently, most identified senolytics are directed against 
members of the BCL-2 protein family. these anti-apoptotic proteins inhibit Bak / Bax polymerization 
on the outer membrane of the mitochondria. Their polymerization produces a cytotoxic cytochrome 
trap, the cytoplasmic cytoplasm triggers the apoptotic pathway of procaspases (Manuscript, 2012) (see 
Figure 5). Studies across different cell types have demonstrated an up-regulation of the BCL-2 family 
members BCL-2, BCL-W, and BCL-XL during senescence (Yosef et al., 2016). Silencing those 
proteins by substances as navitoclax (ABT-263) and TW-37 leads to the activation of programmed cell 
death (Zhu et al., 2016).  
 
Figure 5. Apoptotic pathways. Bcl-2 family members act upstream of mitochondrial- mediated 
apoptosis (based on the diagram from the Zhu et al., 2016). 
 
7.1.2 Metabolism of senescent cells 
 Senescent cells show altered gene expression leading to a specific metabolome and this feature 
can be utilized for their therapeutic targeting. One well-described feature of senescent cells is 
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senescence-associated ß-galactosidase activity (Dimri et al., 1995). A targeted delivery system using 
mesoporous silica nanoparticles coated with galacto-oligosaccharides was developed based on this 
feature (Agostini et al., 2012). While the coated particles cannot be activated in nonsenescent cells, the 
coating is digested in senescent cells and the nanoparticle content can be released. Coated 
nanoparticles containing a cytotoxic drug could release it to the cytoplasm of senescent cells to induce 
apoptosis. Senescent cells also exhibit a secretory profile that is largely conserved between different 
senescent states and cell origins. Modulation of signalling pathways that lead to the proinflammatory 
secretome could therefore neutralize these negative effects of senescent cells. These signalling can be 
influenced by a broad spectrum of drugs (Laberge et al., 2015) For example rapamycin, metformin 
and ruxolitinib (Kirkland et al., 2017). 
 Targeting specific components of SASP could also provide a safer way to mitigate the 
deleterious effects of SASP. Cytokines such as IL-6, IL-8, and matrix-remodelling proteases such as 
ADAM17, could serve as possible targets. One method to block these molecules is the application of 
neutralizing antibodies, which can be developed based on available monoclonal antibodies (Ovadya et 
al., 2018). For example, simvastatin and anti-IL1α substances (Soto-Gamez et al., 2017). 
 Recently, a novel class of senolytic targeting of HSP90 proteins has been identified. HSP90 
comprise a family of ubiquitously expressed molecular chaperones that can promote cell survival via 
stabilization of AKT and ERK which are members of signalling pathways that are up-regulated during 
senescence (Karkoulis et al., 2013). Disruption of the HSP90-AKT interaction inhibited the 
PI3K/AKT pathway, resulting in selective killing of senescent cells of different origins. For example 
geldanamycin, 17-AAG (tanespicin) and 17-DMAG (alvespimycin) (Fuhrmann-Stroissnigg et al., 
2017). Another is mitochondria-targeted tamoxifen (MitoTam), which reduce the adenine nucleotide 
translocase-2 (ANT2) function in oxidative phosphorylation. Inhibition ANT2 is an effective and 
selective drug for senescent and tumour cells (Hubackova et al., 2018) . 
. 
7.2 Cellular senescence specific drugs  
 There is growing interest to target senescent cells therapeutically as a part of anti-ageing and 
rejuvenation strategies. The most straightforward option to remove senescent cells is by their direct 
killing, either by apoptotic (senoptosis) or non-apoptotic means (senolysis) (Zhu et al., 2015). Other 
therapeutic strategies for removal of senescent cells comprise their immune-based clearance by 
antibodies or cytotoxic T-cells (Ovadya et al., 2018). Advantages of directed killing of senescent cells 
include permanent removal of the SASP, elimination of preneoplastic cells, and reducing cancer risk 
from senescent escape (Childs et al., 2015).  
 At present, the scientist is focused on the discovery of pharmacological agents that can induce 
cell death in senescent cells. Many of these agents target upregulated anti-apoptotic system of 
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senescent cells,  such as signalizing through the BCL-2 family of proteins (BCL-2, BCL-XL, and 
BCL-W) (Chang et al., 2015; Yosef et al., 2016). The senolytic molecules ATB-737 and its next 
generation orally available analog ATB-263 (navitoclax) bind to BCL-2, BCL-XL and BCL-W, 
counteract their anti-apoptotic functions and permits senescent cells to initiate apoptosis (Ovadya et 
al., 2018).  
 ATB-737 efficiently eliminates senescent cells that were induced by DNA damage in lungs of 
-irradiated mice, as well as senescent cell formed by p14ARF induction in skin epidermis of transgenic 
mice (Yosef et al., 2016) and positively affected hair growth by inducing hair follicle steam cells 
proliferation.  
 Navitoclax has been shown to eliminate senescent cells from sublethally irradiated mice and 
naturally aged mice, including senescent muscle stem cells and senescent hematopoietic stem cells 
(Chang et al., 2016), which resulted in rejuvenation and partial restoration of hematopoietic function 
of mice. Navitoclax also showed the capacity to eliminate senescent foam cell macrophages from early 
atherosclerotic lesions and block senescent cells-dependent progression of atherosclerosis (Childs et 
al. 2016).  
 On the other side, targeting BCL-2 family of proteins with general inhibitors has been shown 
to be a cause several mechanism-based hematological toxicities, such as neutropenia and 
thrombocytopenia (Cang et al., 2015). Specific BCL-XL inhibitors, such as A1331852 and A1155463, 
are expected to cause less toxicity to nonsenescent cells (Zhu et al., 2017). These substances has been 
shown to induce apoptosis in senescent cholangiocytes and fibroblasts in a mouse model of biliary 
liver fibrosis and reduced liver injury and fibrosis (Moncsek et al., 2018). 
 Intraarticular injection of the BCl-2-targeting UBX0101 compound efficiently eliminated 
senescent cells in articular cartilage and synovium and reduced signs of osteoarthritis in aged mice 
model (Jeon et al., 2017). The combination of the pan-tyrosine kinase inhibitor dasatinib and a 
naturally occurring flavonoid quercetin has been shown to act in selectively killing senescent in tissue 
culture (Schafer et al. 2017). In addition to quercetin, other natural compounds, including fisetin and 
piperlongumine, have been suggested to have senolytic effects (Wang et al., 2016a; Zhu et al., 2017). 
Piperlongumine have good selectivity and pro-apoptotic potency in vitro and acts synergistically with 
navitoclax (Wang et al., 2016b). Targets for piperlongumine is oxidatition rezistence 1 (OX1) protein, 
which protect the senescent cell from reactive oxidation species accumulation. Piperlongumine binds 
to the protein, induces proteasome degradation and apoptosis (Zhang et al., 2018).  
 Other senescence-specific pathways could also be inhibited by small molecules to eliminate 
senescent cells. Disruption of the p53–FOXO4 interaction using a d-retro-inverso peptide (DRI-
FOXO4) that corresponds to the reverse sequence of the FOXO4–p53-binding domain leads to the 
release of p53 from the nucleus and induction of cell-intrinsic apoptosis by catalysing cytochrome c 
release into the cytoplasm from mitochondria. In progeroid and naturally aged mice, short-term 
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treatment with DRI-FOXO4 has been shown to neutralize murine liver chemotoxicity after 
doxorubicin treatment and restore fitness, hair density and renal function (Baar et al., 2017). 
As mentioned above, HSP90 proteins have been identified as novel target for senolysis. In vivo, 
administration of the HSP90 inhibitor 17-DMAG to progeroid mice reduced the senescence signature 
and extended health span (Fuhrmann-Stroissnigg et al., 2017). 
 Antibodies raised against senescence-specific surface antigens, such as CD44 in the senescent 
endothelium (Mun et al., 2010) can be utilised to killing by cytotoxic T cells or to deliver cytotoxic 
nanoparticles for indirect killing of senescent cells. Specific senescent cell antigens could be used to 
raise T cells in vitro armed with chimeric antigen receptors against senescent-specific surface antigens 
for infusion (Grupp et al., 2013). 
 
7.3 Senolytics as anti-ageing drugs 
 Studies performed on a rapidly ageing mouse model with deficiencies in the mitotic 
checkpoint protein BUBR1 have demonstrated a causal link between senescent cells and ageing 
(Hanks et al., 2004). In this model, prematurely aged tissues accumulate high numbers of p16INK4A- 
positive senescent cells which has been shown to trigger natural features of mouse ageing, including 
sarcopenia, cataracts and lipodystrophy. Baker et al. (2008) have demonstrated that genetic 
inactivation of p16INK4A block the formation of senescent cells and attenuates these early-ageing 
phenotypes.  
 Further studies using transgenic mice with senescent cell-killing system INK-ATTAC (INK-
linked apoptosis through targeted activation of caspase) have shown that removal of senescent cells 
from Bub1b-mutant progeroid mice mimicked the ageing phenotype-attenuating effects of p16INK4A 
dysfunction (Baker et al., 2011). In a naturally aged non-progeroid mice clearance of senescent cells 
extended the healthspan and blunted multiple age-related features, including glomerulosclerosis, 
cardiomyocyte hypertrophy, diminished cardiac stress tolerance, cataract formation and lipodystrophy 
as well as cancer (Baker et al., 2016) suggesting that elimination of senescent cells after they arise 
does not have the tumour-promoting side effects. These results spurred wide interest in exploring 
senolysis as a potential therapy to treat age-related symptoms and diseases. 
 Strategies targeting SASP of senescent cells are also under development. Several studies 
suggest that SASP inhibition can improve lifespan and healthspan. For instance the drug rapamycin 
which inhibits the mTOR pathway and effectively suppresses SASP (Laberge et al., 2015) has been 
shown to extend lifespan in a variety of model organisms (de Magalhães et al., 2012). 
 Inhibition of NF-κB signalling (the main transcription factor regulating the SASP) both 
genetically and pharmacologically, has been shown to prevent age-related deterioration in progeroid 
mouse models (Osorio et al., 2012). Telomerase-based anti-ageing therapies are also being developed 
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and a natural product-derived telomerase activator called TA-65 has already been made available. One 
study reported that taking TA-65 may result in the decline of senescent immune system cells in 
patients (Harley et al., 2011). TA-65 can also increase telomerase levels in some mouse tissues and 
was reported to improve health indicators in mice but it did not increase mean or maximum lifespan 
(de Jesus et al., 2011). 
 
7.4 Senolytics as adjuvants of anticancer therapy  
 The findings that senescent cells can fuel malignant phenotypes and tumour growth suggests 
that senotherapies aimed at their removal may be used as a potential supplementary anti-cancer 
therapy. The reactivation of senescence in cancer and the subsequent clearance of senescent cells are 
suggested as therapeutic intervention in the eradication of cancer (Malavolta et al., 2018). It has been 
shown that senescent cells, particularly those that senesce in response to DNA-damaging radiation or 
chemotherapeutic agents, secrete factors that can protect neighbouring tumour cells from being killed 
by those same chemotherapeutic agents (Gilbert and Hemann, 2010; Sun et al., 2012). These 
chemoprotective SASP factors include WNT16B, IL-6, and TIMP-1 (tissue inhibitor of 
metalloproteinases-1). In contrast, at least some SASP components can be chemosensitizing. For 
example, global suppression of the SASP (through NF-κB inhibition) promoted resistance to 
chemotherapy in a mouse lymphoma model (Chien et al., 2011). 
 Existing inhibitors of prosurvival pathways used in cancer therapy may have utility to block 
cell death-resistance pathways promoting senescent cell killing by inducing apoptosis and could be 
even more effective for this use because senescent cells do not proliferate. Therefore, no strong 
selective pressure for development of drug resistance can occur. An example is a cancer drug dasatinib 
which inhibits a broad spectrum of kinases and in combination with a plant flavonoid quercetin has 
been shown to have a pronounced senolytic effect in vitro (Schafer et al., 2017). Several natural 
compounds that activate Nrf2 (nuclear factor erythroid-derived 2-related factor 2) pathway, which is 
involved in complex cytoprotective responses, have been shown to induce cell death or senescence in 
cancer. Senolytic activity shown by some Nrf2-activating compounds could be used to target 
senescent cancer cells (particularly in aged immune-depressed organisms) that escape 
immunosurveillance. The examples of such bioactive compounds are tocotrienols, curcumin, 
epigallocatechin gallate, quercetin, genistein, resveratrol, silybin, allicin, berberine, piperlongumine, 
fisetin and others (Malavolta et al., 2018). Incorporation of these compounds into the therapeutic 







 Senescence in the body can be induced by various stimuli, can even arise from cell fusion, 
which is necessary for embryo development. Another beneficial effect is the suppression of tumour 
development, which however does not apply to chronically present cancer. On the other side, the long-
term presence of senescent cells in tissues has negative effects associated with development of age-
related diseases. By studying the mechanisms of formation and maintenance of senescent cell 
phenotype we can find ways to eliminate them from the body with benefits to rejuvenate organism by 
suppression of age-associated diseases or to improve the current anticancer strategies. New group of 
compounds have been developed to specifically kill senescent cells by reactivating apoptosis. The 
specific (energetic) metabolism of senescent cells can serve as target as well. Another approach is to 
utilize function of immune system to specifically remove senescent cells.  
 In animal models, senolytics seem to be effective against ageing and the diseases associated 
with them. Effective agents are anti-apoptotic agents or antioxidant protection such as piperlongumine. 
others are effective in the fight against cancer by stopping the cell cycle of tumour cells and inducing 
senescence. Testing these substances for senescent cells and monitoring their effect is a promising 
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